Display options
Cite
Adsit S, Zaldivar ER, Sofen H, et al. Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials. Adv Ther. 2017;34(7):1772doi: 10.1007/s12325-017-0563-2.
Adsit, S., Zaldivar, E. R., Sofen, H., Dei-Cas, I., Maldonado-García, C., Peñaranda, E. O., Puig, L., Meng, X., Fox, T., & Guana, A. (2017). Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials. Advances in therapy, 34(7), 1772. https://doi.org/10.1007/s12325-017-0563-2
Adsit, Sandra, et al. "Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials." Advances in therapy vol. 34,7 (2017): 1772. doi: https://doi.org/10.1007/s12325-017-0563-2
Adsit S, Zaldivar ER, Sofen H, Dei-Cas I, Maldonado-García C, Peñaranda EO, Puig L, Meng X, Fox T, Guana A. Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials. Adv Ther. 2017 Jul;34(7):1772. doi: 10.1007/s12325-017-0563-2. PMID: 28589404; PMCID: PMC5504197.
Copy Download .nbib Format: NLM
Share it on

Adv Ther. 2017 Jul;34(7):1772. doi: 10.1007/s12325-017-0563-2.

Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials.

Advances in therapy

Sandra Adsit, Enrique Rivas Zaldivar, Howard Sofen, Ignacio Dei-Cas, César Maldonado-García, Elkin O Peñaranda, Luís Puig, Xiangyi Meng, Todd Fox, Adriana Guana

Affiliations

  1. TCR Medical Corporation, San Diego, CA, USA. [email protected].
  2. Dermos, Guatemala City, Guatemala.
  3. UCLA School of Medicine, Los Angeles, CA, USA.
  4. Halitus, Buenos Aires, Argentina.
  5. Centro Dermatológico "Dr. Ladislao de la Pascua", Mexico City, Mexico.
  6. Riesgo de Fractura S.A., Bogota, Colombia.
  7. Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  8. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  9. Novartis Pharma AG, Basel, Switzerland.

PMID: 28589404 PMCID: PMC5504197 DOI: 10.1007/s12325-017-0563-2

[No abstract available.]

Publication Types